Phase 1 expansion trial with crizotinib in ROS1 rearrangement-positive NSCLC patients demonstrated marked antitumor activity with 72% ORR and 17.6 months median DOR, which led to its FDA approval in 2016 (56). Here, ROS1 is linked to non-small cell lung carcinoma.